Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com) presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18, 2011 in Cambridge, MA.
In a presentation titled Clinical Development of a Modified, Self-Potentiating HER2 Peptide Vaccine in Breast and Prostate Cancer Patients, Dr. Eric von Hofe, Ph.D., President of Antigen Express, presented positive preliminary results from an ongoing Phase 2 trial of AE37 in breast cancer patients. At a median of 17 months follow-up, the relapse rate in patients with low levels of HER2 expression treated with AE37 is half that of the same patient population in the control arm. The primary endpoint of the study is to demonstrate a significant reduction in relapse rate in AE37 patients after 24 months follow-up.
The Company has also concluded a Phase I trial in patients with prostate cancer. All trials conducted to date have shown that AE37 is safe, well-tolerated, and induces the desired immune response.
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths